1. Home
  2. IPHA vs SSP Comparison

IPHA vs SSP Comparison

Compare IPHA & SSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPHA
  • SSP
  • Stock Information
  • Founded
  • IPHA 1999
  • SSP 1878
  • Country
  • IPHA France
  • SSP United States
  • Employees
  • IPHA N/A
  • SSP N/A
  • Industry
  • IPHA Biotechnology: Pharmaceutical Preparations
  • SSP Broadcasting
  • Sector
  • IPHA Health Care
  • SSP Industrials
  • Exchange
  • IPHA Nasdaq
  • SSP Nasdaq
  • Market Cap
  • IPHA 148.3M
  • SSP 203.8M
  • IPO Year
  • IPHA 2019
  • SSP 1988
  • Fundamental
  • Price
  • IPHA $1.79
  • SSP $2.10
  • Analyst Decision
  • IPHA Strong Buy
  • SSP Buy
  • Analyst Count
  • IPHA 1
  • SSP 2
  • Target Price
  • IPHA $11.50
  • SSP $5.75
  • AVG Volume (30 Days)
  • IPHA 779.8K
  • SSP 612.1K
  • Earning Date
  • IPHA 09-12-2024
  • SSP 02-21-2025
  • Dividend Yield
  • IPHA N/A
  • SSP N/A
  • EPS Growth
  • IPHA N/A
  • SSP N/A
  • EPS
  • IPHA N/A
  • SSP N/A
  • Revenue
  • IPHA $36,202,722.00
  • SSP $2,397,162,000.00
  • Revenue This Year
  • IPHA N/A
  • SSP $10.34
  • Revenue Next Year
  • IPHA $101.65
  • SSP N/A
  • P/E Ratio
  • IPHA N/A
  • SSP N/A
  • Revenue Growth
  • IPHA N/A
  • SSP 1.66
  • 52 Week Low
  • IPHA $1.29
  • SSP $1.68
  • 52 Week High
  • IPHA $3.51
  • SSP $9.35
  • Technical
  • Relative Strength Index (RSI)
  • IPHA 45.92
  • SSP 45.25
  • Support Level
  • IPHA $1.64
  • SSP $1.91
  • Resistance Level
  • IPHA $1.87
  • SSP $2.77
  • Average True Range (ATR)
  • IPHA 0.12
  • SSP 0.21
  • MACD
  • IPHA -0.04
  • SSP 0.01
  • Stochastic Oscillator
  • IPHA 28.66
  • SSP 29.47

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

Share on Social Networks: